For lung cancer, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), mesothelin (MSLN), prostate stem cell antigen (PSCA), mucin 1 (MUC1), carcinoembryonic antigen (CEA), tyrosine kinase‐like orphan receptor 1 (ROR1), PD‐L1 and CD80/CD86 are currently being evaluated as potential targets for the CAR‐T therapy.89 This evidence concerns the gene ERBB2 and lung carcinoma.